Market Eyes LiveStryker Corporation (SYK) Stock Rating & Analysis
MELANY's data-driven read on Stryker Corporation · Surgical & Medical Instruments & Apparatus.
Stryker designs, manufactures, and markets medical equipment, instruments, consumable supplies, and implantable devices, including hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. It is among the three largest competitors in reconstructive orthopedic implants and the leader in operating room equipment. About a fourth of its total revenue comes from outside the US.
Why SYK scores 56/100
MELANY scores Stryker Corporation 56/100 by weighing eight factors. Here is how SYK breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 19.8x, earnings growth accelerating
Margins, returns on capital, and balance-sheet strength.
- Gross margin 65%
Direction and relative strength of the recent share-price trend.
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for SYK
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
Stryker Corporation sits in the Healthcare sector theme, which MELANY currently rates 37/100 for strength. Theme strength feeds SYK's momentum and catalyst factors above.
Tracking SYK
Stryker Corporation rates Hold right now, so MELANY is not flagging a fresh entry. Create a free account to add SYK to your watchlist and get alerted the moment the rating changes.
How MELANY rates SYK
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Stryker Corporation's 56/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about SYK
Is Stryker Corporation (SYK) a buy?
As of 2026-08-18, MELANY rated Stryker Corporation Hold with a composite score of 56/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Stryker Corporation's MELANY score?
Stryker Corporation (SYK) has a MELANY composite score of 56/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the SYK stock rating calculated?
MELANY scores SYK from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Stryker Corporation stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Stryker Corporation (SYK) Hold with a composite of 56/100 as of 2026-08-18. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the SYK stock price forecast?
MELANY does not publish price targets or forecasts for SYK. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 56/100 across eight factors for Stryker Corporation, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is SYK stock overvalued or undervalued?
MELANY's valuation factor currently reads 49/100 for Stryker Corporation, where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives SYK's read.
What price should I buy SYK at?
MELANY is not flagging a fresh entry for SYK at its current Hold rating, so there is no entry zone to publish right now. Watchlisting SYK in the free app gets you alerted the moment that changes.
What are the risks of buying SYK stock?
The top risks MELANY currently flags for Stryker Corporation: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Stryker Corporation a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 73/100 for Stryker Corporation, and earnings track record, at 60/100. The 56/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will SYK stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 44/100 for SYK right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this SYK rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-18. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores SYK continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
SYK's live rating and alerts are free either way. The app is our flagship.